dr. rotow on the implications of next-generation alk inhibitors in nsclc
Published 4 years ago • 110 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
1:14
dr. rotow on first-line brigatinib versus crizotinib in alk nsclc
-
0:52
dr. rotow on remaining questions with brigatinib in alk nsclc
-
1:11
dr. rotow on brigatinib safety profile in alk nsclc
-
6:27
alk inhibitor sequencing in nsclc
-
8:17
third-generation alk inhibitors for nsclc
-
0:53
dr. stinchcombe discusses differences in toxicity profiles among alk inhibitors in nsclc
-
0:59
dr. johung on prognosis of patients with alk-rearranged nsclc and brain metastases
-
26:24
the therapeutic implications of eml4/alk, ros-1 and other actionable biomarkers
-
22:21
the therapeutic implications of eml4/alk, ros-1 and other new biomarkers
-
8:02
updates informing the management of alk-rearranged mnsclc
-
1:05
dr. aggarwal on emerging treatment approaches in alk nsclc
-
4:37
fda approval of brigatinib for alk nsclc
-
1:26
dr. solomon on the results of the phase 3 crown study in alk-positive nsclc
-
1:48
dr. chow on the use of ceritinib in alk nsclc metastatic to the brain
-
1:52
dr. drilon on the utility of brigatinib in alk nsclc
-
6:12
experience with ceritinib for alk nsclc
-
0:51
dr. bazhenova on ongoing clinical trials with immunotherapy in nsclc
-
1:24
dr. halmos on recent advancements in non–small cell lung cancer
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc